Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Company (Lilly) is a US based innovation driven pharmaceutical company. It carries out the discovery, development, manufacture and marketing of products. The company’s product portfolio consists of neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceutical products. The company’s research efforts are mainly focused on five therapeutic domains, namely, cancer; endocrine diseases such as diabetes, obesity, and musculoskeletal disorders; central nervous system; autoimmune diseases; and cardiovascular diseases. The company’s product are sold in several countries across the world.

Eli Lilly and Company Key Recent Developments

Apr 24, 2014: Lilly Reports First-Quarter 2014 Results
Apr 09, 2014: Lilly and T1D Exchange Announce Research Collaboration to Inform Development of New Initiatives to Advance Diabetes Care
Apr 08, 2014: Lilly Responds to Verdict in Case of Terrence Allen, et al. v. Takeda
Mar 05, 2014: Lilly and Novast Announce Ground Breaking of State of the Art Manufacturing Facility Expansion in Nantong, China
Feb 26, 2014: CDC Foundation and Lilly to Address Unsafe Injection Practices in U.S. Healthcare Settings

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review
Table of Contents

Section 1 - About the Company 5
Eli Lilly and Company - Key Facts 5
Eli Lilly and Company - Key Employees 6
Eli Lilly and Company - Key Employee Biographies 8
Eli Lilly and Company - Major Products and Services 9
Eli Lilly and Company - Pharmaceutical Pipeline Products Data 11
Eli Lilly and Company, Pipeline Products by Therapy Area 11
Eli Lilly and Company, Pipeline Products by Development Phase 12
Eli Lilly and Company - History 21
Eli Lilly and Company - Company Statement 29
Eli Lilly and Company - Locations And Subsidiaries 33
Head Office 33
Other Locations and Subsidiaries 33
Eli Lilly and Company - Key Manufacturing Facilities 40
Section 2 - Company Analysis 41
Eli Lilly and Company - Business Description 41
Business Description - Pharmaceutical Products 41
Pharmaceutical Products - Overview 41
Pharmaceutical Products - Financials 42
Pharmaceutical Products - Key Strategies 42
Eli Lilly and Company - Corporate Strategy 43
Eli Lilly and Company - SWOT Analysis 44
SWOT Analysis - Overview 44
Eli Lilly and Company - Strengths 44
Strength - Emphasis on Research 44
Strength - Marketed Product Portfolio 44
Strength - Strategic Collaborations 44
Eli Lilly and Company - Weaknesses 45
Weakness - Geographical Concentration 45
Weakness - Product Litigations 45
Eli Lilly and Company - Opportunities 45
Opportunity - New Product Approvals and Launches 45
Opportunity - Product Pipeline 45
Opportunity - Key Business Initiatives 45
Eli Lilly and Company - Threats 46
Threat - Uncertain RandD Outcomes 46
Threat - Competitive Landscape 46
Threat - Non-compliance of Government Regulations 46
Eli Lilly and Company - Key Competitors 47
Section 3 - Company Financial Ratios 48
Financial Ratios - Capital Market Ratios 48
Financial Ratios - Annual Ratios 48
Performance Chart 50
Financial Performance 50
Financial Ratios - Interim Ratios 51
Financial Ratios - Ratio Charts 52
Section 4 - Company's Lifesciences Financial Deals and Alliances 53
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 53
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Type, 2008 to YTD 2014 54
Eli Lilly and Company, Recent Deals Summary 55
Section 5 - Company's Recent Developments 56
Eli Lilly and Company, Recent Developments 56
Apr 24, 2014: Lilly Reports First-Quarter 2014 Results 56
Apr 09, 2014: Lilly and T1D Exchange Announce Research Collaboration to Inform Development of New Initiatives to Advance Diabetes Care 57
Apr 08, 2014: Lilly Responds to Verdict in Case of Terrence Allen, et al. v. Takeda 58
Mar 05, 2014: Lilly and Novast Announce Ground Breaking of State of the Art Manufacturing Facility Expansion in Nantong, China 58
Feb 26, 2014: CDC Foundation and Lilly to Address Unsafe Injection Practices in U.S. Healthcare Settings 59
Jan 30, 2014: Lilly Reports Fourth-Quarter and Full-Year 2013 Results 59
Jan 30, 2014: Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus and Lantus SoloStar 61
Jan 22, 2014: Eli Lilly and Company Joins the National Pharmaceutical Council 61
Jan 14, 2014: Genmab Announces DuoBody Platform Collaboration With Eli Lilly and Company 62
Jan 02, 2014: Lilly Sets Dates and Conference Calls for 2014 Financial Guidance and Fourth-Quarter 2013 Financial Results Announcements 62
Section 6 - Appendix 63
Methodology 63
Ratio Definitions 63
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables

Eli Lilly and Company, Key Facts 5
Eli Lilly and Company, Key Employees 6
Eli Lilly and Company, Key Employee Biographies 8
Eli Lilly and Company, Major Products and Services 9
Eli Lilly and Company, Number of Pipeline Products by Therapy Area 11
Eli Lilly and Company, Number of Pipeline Products by Development Stage 12
Eli Lilly and Company, Pipeline Products By Therapy Area and Development Phase 13
Eli Lilly and Company, History 21
Eli Lilly and Company, Subsidiaries 33
Eli Lilly and Company, Key Manufacturing Facilities 40
Eli Lilly and Company, Key Competitors 47
Eli Lilly and Company, Ratios based on current share price 48
Eli Lilly and Company, Annual Ratios 48
Eli Lilly and Company, Interim Ratios 51
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 53
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Type, 2008 to YTD 2014 54
Eli Lilly and Company, Recent Deals Summary 55
Currency Codes 63
Capital Market Ratios 63
Equity Ratios 64
Profitability Ratios 64
Cost Ratios 65
Liquidity Ratios 65
Leverage Ratios 66
Efficiency Ratios 66

List of Figures

Eli Lilly and Company, Pipeline Products by Therapy Area 11
Eli Lilly and Company, Pipeline Products by Development Phase 12
Eli Lilly and Company, Performance Chart (2009 - 2013) 50
Eli Lilly and Company, Ratio Charts 52
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 53
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals by Type, 2008 to YTD 2014 54

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.